{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-164515","form_type":"8-K","ticker":null,"cik":"0001850079","company_name":"Telesis Bio Inc.","filed_at":"2023-06-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:41.223474+00:00","generated_at":"2026-06-14T04:16:53.894168+00:00","sec_items":["3.02","3.03","5.02","5.03","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Telesis Bio closes $28M private placement of preferred stock and warrants; appoints Paul Meister to board","bullets":["Initial gross proceeds of $28.0M from private placement of redeemable convertible preferred stock and warrants.","Warrants could provide up to $46.2M in additional proceeds if cash exercised.","Financing led by Novalis LifeSciences; includes participation from Northpond Ventures, BroadOak, and CEO affiliate M-185 Corp.","Paul Meister, partner at Novalis LifeSciences, appointed to board effective June 5, 2023, expanding board from 7 to 8 directors.","Proceeds to be used for general corporate purposes."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-164515","json":"https://secwatch.observer/filing/0001193125-23-164515.json","markdown":"https://secwatch.observer/filing/0001193125-23-164515.md","text":"https://secwatch.observer/filing/0001193125-23-164515.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1850079/000119312523164515/0001193125-23-164515-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1850079/000119312523164515/d463439d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T04:16:53.894168+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d623cbf31a","claim":"Paul Meister was appointed as director at Telesis Bio Inc..","evidence_excerpt":"Paul Meister, a partner at Novalis LifeSciences LLC, was appointed as a director of the Company to fill the resulting vacancy.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1850079/000119312523164515/0001193125-23-164515-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"director"}],"fact_type":"executive_change"},{"claim_id":"06ca05a4972c52ba9dfad215003e44d9afd5f0fb","claim":"Telesis Bio Inc.: Filed Certificate of Designation establishing Redeemable Convertible Preferred stock.","evidence_excerpt":"Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. In connection with the closing of the Private Placement, the Company filed with the Secretary of State of the State of Delaware the Certificate of Designation attached hereto as Exhibit 3.1 and incorporated herein by reference. The Certificate of Designation establishes and designates the Redeemable Convertible Preferred and the rights, preferences and privileges thereof.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1850079/000119312523164515/0001193125-23-164515-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"}],"fact_type":"governance_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}